Please refer to the vial lable for the specific concentration.
Purification:
Protein A/G
Molecular Weight:
13.9 kDa
Immunogen:
TIGIT
Buffer:
Supplied in PBS
Storage:
Short Term: 2-8 degree. Long Term: -20 degree. Avoid multiple freeze-thaw cycles.
General Information
Background:
T cell immunoreceptor with Ig and ITIM domains(TIGIT), also named as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane do-maincontaining protein 3 (VSTM3) and Washington University cell adhesion molecule (WUCAM), is a co-inhibitory molecule belonging to the immunoglobulin superfamily that was first discovered in 2009. It consists of an extracellular immunoglobulin variable (IgV) domain, a type I transmembrane domain and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-like motif. TIGIT is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance.
Synonyms:
T cell immunoreceptor with Ig and ITIM domains, TIGIT, VSIG9, VSTM3, WUCAM
Note
For research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals.
+1 929 202 3014
info@abvigenus.com